Thermo Fisher Scientific Inc.
TMOHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeThermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. With a market capitalization of $226.94B, it sits in mega-cap territory. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
Market Cap
$226.94B
Beta
0.85
P/E (TTM)
33.00
P/E (Fwd)
22.30
EPS (TTM)
$18.60
EPS (Fwd)
$27.53
ROE
13.5%
ROA
5.1%
Cash
$4.06B
Total Debt
$42.55B
Free CF
$6.24B
52W Change
27.2%
Annual Financials
Cash vs Debt
Where TMO stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, TMO finished 16.29% above its 150-day moving average ($516.36) and 12.28% above its 200-day moving average ($534.84). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TMO overbought or oversold?
At the September 2, 2026 close, TMO's RSI(14) was 48.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $4.06B in cash, though total debt stands at $42.55B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $6.24B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 13.5%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $39.21B to $44.56B.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Thermo Fisher Scientific Inc. and its sector.